PMID- 11477561
OWN - NLM
STAT- MEDLINE
DCOM- 20010809
LR  - 20190708
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 93
IP  - 4
DP  - 2001 Aug 15
TI  - MHC class I negative phenotype of disseminated tumor cells in bone marrow is 
      associated with poor survival in R0M0 breast cancer patients.
PG  - 566-70
AB  - Changing the major histocompatibility complex (MHC) class I phenotype is a 
      pivotal strategy of tumor cells to circumvent an effective immune response and is 
      associated with tumor progression in cancer patients. Epithelial cells in bone 
      marrow have been detected in various tumor types, but the clinical observation 
      that only a portion of the patients with a positive bone marrow status develops 
      solid bone metastasis suggests a certain molecular equipment of the isolated 
      tumor cells as a prerequisite for metastatic formation. In the present study the 
      prognostic impact of the MHC class I phenotype of disseminated epithelial cells 
      in bone marrow was evaluated in a cohort of 30 curatively resected (R0) patients 
      without distant metastases (M0) (designated R0M0) who had minimal residual 
      disease. Immunocytochemical analysis using the alkaline/anti-alkaline immunogold 
      double staining procedure revealed a heterogeneous MHC class I expression profile 
      [monoclonal antibody (mAb) W6/32] of the epithelial cells (mAb CK2). In 16 
      patients (53.3%) all epithelial cells were human leukocyte antigen (HLA) class 
      I-positive (CK2+//W6/32+ phenotype). Eight patients (26.7%) showed complete loss 
      of the HLA class I molecules (CK2+//W6/32- phenotype) and in 6 patients (20%) 
      partial loss of HLA class I expression was found (CK2+//W6/32+ and - phenotype). 
      CK2+ cells with the HLA class I negative phenotype (CK2+//W6/32- phenotype and 
      CK2+//W6/32+ and - phenotype) were often derived from poorly differentiated (G3) 
      primary breast carcinomas (p = 0.036) and were associated with short survival of 
      the R0M0 patients (follow-up 15-98 months, log rank p = 0.072). These findings 
      support the necessity to develop immmunotherapeutic strategies leading to the 
      restoration of MHC class I positive phenotype.
CI  - Copyright 2001 Wiley-Liss, Inc.
FAU - Zia, A
AU  - Zia A
AD  - Klinikum Grosshadern, Department of Surgery, Ludwig-Maximilians University, 
      Munich, Germany.
FAU - Schildberg, F W
AU  - Schildberg FW
FAU - Funke, I
AU  - Funke I
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 68238-35-7 (Keratins)
SB  - IM
MH  - Antibodies, Monoclonal/immunology
MH  - Bone Marrow/*pathology
MH  - Breast Neoplasms/*immunology/*pathology
MH  - Down-Regulation
MH  - Epithelial Cells/immunology/pathology
MH  - Female
MH  - HLA Antigens/immunology
MH  - Histocompatibility Antigens Class I/immunology
MH  - Humans
MH  - Keratins/immunology
MH  - Middle Aged
MH  - Neoplasm, Residual
MH  - Phenotype
MH  - Prognosis
MH  - Survival Rate
EDAT- 2001/07/31 10:00
MHDA- 2001/08/10 10:01
CRDT- 2001/07/31 10:00
PHST- 2001/07/31 10:00 [pubmed]
PHST- 2001/08/10 10:01 [medline]
PHST- 2001/07/31 10:00 [entrez]
AID - 10.1002/ijc.1362 [pii]
AID - 10.1002/ijc.1362 [doi]
PST - ppublish
SO  - Int J Cancer. 2001 Aug 15;93(4):566-70. doi: 10.1002/ijc.1362.